China Pharma Holdings ( (CPHI) ) has released a notification of late filing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Pharma Holdings, Inc. has filed a Form 12b-25, notifying investors that it will delay its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The company says it cannot meet the March 31, 2026 deadline for the annual filing due to the time required to compile, disseminate and review all information for the report without incurring undue hardship and expense.
Management expects to file the Form 10-K (Yearly Report) within the allowed grace period, no later than 15 calendar days after the original due date, implying a target on or before mid-April 2026. The company also confirms that all other required periodic reports over the past 12 months have been filed on time, limiting broader concerns about its reporting discipline.
The notification signals that China Pharma anticipates significant changes in its 2025 operating results compared with 2024. Preliminary figures show revenue slipping modestly to $4.1 million from $4.5 million, but cost of revenue dropping sharply to about $4.3 million from $6.5 million, leading to a substantial improvement in gross loss.
Gross loss is expected to narrow to roughly $0.1 million in 2025 from about $2.0 million in 2024, with the gross loss margin shrinking from approximately 43.8% to around 3.2%. Net loss is projected to improve as well, falling to about $3.19 million from $4.74 million a year earlier, though these numbers are still management estimates and may change once the audit and financial statement preparation are complete.
Investors should treat these figures as forward-looking and subject to revision in the final Form 10-K (Yearly Report). China Pharma states that it will provide more detailed narrative and quantitative analysis of its 2025 performance once the filing is made, offering a clearer view of what drove the improved cost structure and reduced losses.
The company indicates it is continuing its normal compliance efforts and working through the remaining steps needed to finalize the annual report. The notification is signed on behalf of China Pharma Holdings, Inc. by Chief Executive Officer Zhilin Li on April 1, 2026, formally committing the company to complete the delayed Form 10-K (Yearly Report) within the extended timeframe.
The most recent analyst rating on (CPHI) stock is a Sell with a $0.79 price target. To see the full list of analyst forecasts on China Pharma Holdings stock, see the CPHI Stock Forecast page.
Spark’s Take on CPHI Stock
According to Spark, TipRanks’ AI Analyst, CPHI is a Neutral.
The score is held down primarily by very weak financial performance (large losses, extremely negative ROE, and negative cash flows) and bearish technicals (below major moving averages with negative MACD). Corporate actions provide some strategic positives (pipeline patents and capital-structure flexibility), but dilution/reverse-split risk and loss-making fundamentals keep the overall score low.
To see Spark’s full report on CPHI stock, click here.
More about China Pharma Holdings
Average Trading Volume: 50,345
Technical Sentiment Signal: Sell
Current Market Cap: $3.06M
See more insights into CPHI stock on TipRanks’ Stock Analysis page.